Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer.

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73600846" target="_blank" >RIV/61989592:15110/20:73600846 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/20:00115906 RIV/00216208:11120/20:43920073 RIV/00216208:11140/20:10410198 RIV/00216208:11150/20:10410198 and 5 more

Result on the web

<a href="https://pubmed.ncbi.nlm.nih.gov/32234916/" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/32234916/</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.14182" target="_blank" >10.21873/anticanres.14182</a>

Result language

angličtina

Original language name

Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer.

Original language description

Aim: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and methods: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. Results: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. Conclusion: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30203 - Respiratory systems

Project

<a href="/en/project/NV17-30748A" target="_blank" >NV17-30748A: A new approach by combination of functional imaging and tumor genomics for non-invasive phenotyping and monitoring of therapy of lung carcinomas</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

ANTICANCER RESEARCH

ISSN

0250-7005

e-ISSN

—

Volume of the periodical

40

Issue of the periodical within the volume

4

Country of publishing house

GR - GREECE

Number of pages

9

Pages from-to

2209-2217

UT code for WoS article

000522734400050

EID of the result in the Scopus database

2-s2.0-85082791859